190 related articles for article (PubMed ID: 8223809)
1. Magnetic resonance imaging in juvenile Canavan disease.
Toft PB; Geiss-Holtorff R; Rolland MO; Pryds O; Müller-Forell W; Christensen E; Lehnert W; Lou HC; Ott D; Hennig J
Eur J Pediatr; 1993 Sep; 152(9):750-3. PubMed ID: 8223809
[TBL] [Abstract][Full Text] [Related]
2. [Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease].
Engelbrecht V; Rassek M; Gärtner J; Kahn T; Mödder U
Rofo; 1995 Sep; 163(3):238-44. PubMed ID: 7548871
[TBL] [Abstract][Full Text] [Related]
3. A case of Canavan disease: the first biochemically proven case in a Japanese girl.
Hamaguchi H; Nihei K; Nakamoto N; Ezoe T; Naito H; Hara M; Yokota K; Inoue Y; Matsumoto I
Brain Dev; 1993; 15(5):367-71. PubMed ID: 8279652
[TBL] [Abstract][Full Text] [Related]
4. Atypical clinical and radiological course of a patient with Canavan disease.
Sarret C; Boespflug-Tanguy O; Rodriguez D
Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
[TBL] [Abstract][Full Text] [Related]
5. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.
Janson CG; McPhee SW; Francis J; Shera D; Assadi M; Freese A; Hurh P; Haselgrove J; Wang DJ; Bilaniuk L; Leone P
Neuropediatrics; 2006 Aug; 37(4):209-21. PubMed ID: 17177147
[TBL] [Abstract][Full Text] [Related]
6. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion.
Moreno A; Ross BD; Blüml S
J Neurochem; 2001 Apr; 77(1):347-50. PubMed ID: 11279290
[TBL] [Abstract][Full Text] [Related]
7. Restricted diffusion in Canavan disease.
Srikanth SG; Chandrashekar HS; Nagarajan K; Jayakumar PN
Childs Nerv Syst; 2007 Apr; 23(4):465-8. PubMed ID: 17219235
[TBL] [Abstract][Full Text] [Related]
8. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease.
Wittsack HJ; Kugel H; Roth B; Heindel W
J Magn Reson Imaging; 1996; 6(6):889-93. PubMed ID: 8956134
[TBL] [Abstract][Full Text] [Related]
9. Use of localized proton nuclear magnetic resonance spectroscopy in Canavan's disease.
Aydinli N; Calişkan M; Calay M; Ozmen M
Turk J Pediatr; 1998; 40(4):549-57. PubMed ID: 10028864
[TBL] [Abstract][Full Text] [Related]
10. [A case of Canavan-Van Bogaert-Bertrand leukodystrophy].
Mikhaĭlova SV; Zakharova EIu; Bukina AM; Il'ina ES; Pokrovskaia AIa; Fedoniuk ID; Bembeeva RTs; Petrukhin AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):50-4. PubMed ID: 15270300
[No Abstract] [Full Text] [Related]
11. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.
Assadi M; Janson C; Wang DJ; Goldfarb O; Suri N; Bilaniuk L; Leone P
Eur J Paediatr Neurol; 2010 Jul; 14(4):354-9. PubMed ID: 20034825
[TBL] [Abstract][Full Text] [Related]
12. Atypical MRI findings in Canavan disease: a patient with a mild course.
Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
[TBL] [Abstract][Full Text] [Related]
13. [Canavan disease or N-acetyl aspartic aciduria: a case report].
Boughamoura L; Chaabane F; Tilouche S; Chabchoub I; Kabachi N; Tlili K; Yacoub M; Essoussi AS
Arch Pediatr; 2007 Feb; 14(2):173-6. PubMed ID: 17196380
[TBL] [Abstract][Full Text] [Related]
14. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
15. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
16. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
17. Cerebral metabolism in experimental hydrocephalus: an in vivo 1H and 31P magnetic resonance spectroscopy study.
Braun KP; van Eijsden P; Vandertop WP; de Graaf RA; Gooskens RH; Tulleken KA; Nicolay K
J Neurosurg; 1999 Oct; 91(4):660-8. PubMed ID: 10507389
[TBL] [Abstract][Full Text] [Related]
18. Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study.
Simone IL; Tortorella C; Federico F; Liguori M; Lucivero V; Giannini P; Carrara D; Bellacosa A; Livrea P
J Neurol Sci; 2001 Jan; 182(2):143-50. PubMed ID: 11137520
[TBL] [Abstract][Full Text] [Related]
19. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
20. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
